Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

Pennsylvania

Phase 3 cancer trials in Pennsylvania

127 Phase 3 cancer studies are recruiting participants at sites in 77 cities across Pennsylvania as of November 18, 2026, according to ClinicalTrials.gov.

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Browse Pennsylvania by city

Cities with the most studies recruiting right now.

Every Pennsylvania city with a recruiting study

By research area: Lung Cancer (42), Breast Cancer (26), Lymphoma (21), Prostate Cancer (17), Melanoma (13), Pancreatic Cancer (8).

Philadelphia (73), Pittsburgh (63), Hershey (28), Danville (23), York (23), Wilkes-Barre (21), Allentown (19), Bethlehem (18), Erie (17), Lewisburg (16), Monroeville (16), Lancaster (15), Dickson City (14), Sayre (14), West Reading (14), Chambersburg (13), Ephrata (13), Lebanon (13), Chadds Ford (12), Gettysburg (12), Hazleton (12), Mechanicsburg (12), Willow Grove (12), Greensburg (11), Harrisburg (11), Media (11), Wynnewood (11), Scranton (9), Bryn Mawr (8), East Stroudsburg (8), Farrell (8), Jefferson Hills (8), Johnstown (8), Paoli (8), Pottsville (8), Wexford (8), Beaver (7), Carlisle (7), Natrona Heights (7), New Castle (7), Williamsport (7), Cranberry Township (6), Hanover (6), N. Huntingdon (6), Seneca (6), Washington (6), Bala-Cynwyd (5), East Norriton (5), Indiana (5), Meadville (5), Moon Township (5), Uniontown (5), West Mifflin (5), Broomall (4), Butler (4), Easton (4), Horsham (4), McKeesport (4), Meadowbrook (4), Mount Pleasant (4), Phoenixville (4), Altoona (3), Fountain Hill (2), Furlong (2), Quakertown (2), Reading (2), Sellersville (2), Stroudsburg (2), West Chester (2), Bensalem (1), Darby (1), Doylestown (1), Dunmore (1), Langhorne (1), Newton (1), Philidelphia (1), Pottstown (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Breast cancer: recently updated in Pennsylvania

Basic details from each study's public record (the 12 most recently updated of 127). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Philadelphia · York
    Registry record
    NCT06393374 · updated
  2. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Danville · Dickson City · Hazleton · and 6 more U.S. locations
    Registry record
    NCT07391774 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Pennsylvania on ClinicalTrials.gov.

Lung cancer: recently updated in Pennsylvania

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Allentown · Bethlehem · Bryn Mawr · and 13 more U.S. locations
    Registry record
    NCT06498635 · updated
  2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Recruiting in
    Philadelphia · Pittsburgh
    Registry record
    NCT06767514 · updated
  3. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Bethlehem · Philadelphia
    Registry record
    NCT06422143 · updated
  4. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Bethlehem
    Registry record
    NCT06623422 · updated
  5. A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Mirati Therapeutics Inc.
    Recruiting in
    York
    Registry record
    NCT06875310 · updated
  6. JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Texas Southwestern Medical Center
    Recruiting in
    Pittsburgh
    Registry record
    NCT02468024 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Pennsylvania on ClinicalTrials.gov.

Lymphoma: recently updated in Pennsylvania

  1. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Philadelphia
    Registry record
    NCT06337318 · updated
  2. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Nuvation Bio Inc.
    Recruiting in
    Philadelphia · Pittsburgh
    Registry record
    NCT05303519 · updated
  3. A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Broomall · York
    Registry record
    NCT06136559 · updated
  4. ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Newave Pharmaceutical Inc
    Recruiting in
    Pittsburgh
    Registry record
    NCT07342478 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Pennsylvania on ClinicalTrials.gov.

Ask about studies in Pennsylvania

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call